BioSpace News Archive

Galderma announced that the U.S. Food and Drug Administration has accepted its Biologics License Applications for nemolizumab for the treatment of prurigo nodularis and for adolescents and adults with moderate to severe atopic dermatitis.

enGene Holdings Inc. announced that it has agreed to sell 20 million of its common shares at a price per share of $10.00, representing a 31% premium over the closing price on February 13, 2024.

TScan Therapeutics, Inc. today announced the Company will host a virtual key opinion leader (KOL) event to discuss updated results from its Phase 1 heme malignancies study and highlights from its oral presentation at the 2024 Tandem Meetings.

Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab) today announced the company will issue a press release reporting its fourth quarter and full year 2023 financial results and providing a business update on March 7, 2024, at 7:00 am Eastern Time.

Beactica Therapeutics AB announced that its TEAD programme has been selected for a late-breaking presentation at the American Association for Cancer Research’s Annual Meeting 2024.

Carrick Therapeutics today announced that the first patient has been dosed in its Phase 1b/2 clinical trial evaluating the combination of samuraciclib (CT7001).

Ocuphire Pharma, Inc. today announced the appointments of Ash Jayagopal, Ph.D. M.B.A. as Chief Scientific and Development Officer, and Nirav Jhaveri, C.F.A., M.B.A. as Chief Financial Officer, effective today.

Citius Pharmaceuticals, Inc. today announced the resubmission of the Company’s Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for LYMPHIR™ (denileukin diftitox), an IL-2-based immunotherapy for the treatment of patients with relapsed or refractory cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy.

BlossomHill Therapeutics today announced Jingrong Jean Cui, Ph.D., Co-Founder, President and Chief Executive Officer of BlossomHill Therapeutics, has been elected to the National Academy of Engineering (NAE).

Kiromic BioPharma, Inc. (OTCQB: KRBP) (“Kiromic” or the “Company”) announces continued encouraging clinical findings from the most recent follow-up visit of the first patient enrolled in Deltacel-01, the Company’s Phase 1 clinical trial evaluating Deltacel ™ for the treatment of stage 4 metastatic non-small lung cancer.